TITLE:
Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome

CONDITION:
Werner's Syndrome

INTERVENTION:
growth hormone

SUMMARY:

      OBJECTIVES:

      I. Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a
      patient with Werner's syndrome and osteoporosis.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth
      factor 1 daily for 7 months. The dose is adjusted according to the serum hormone level and
      biological markers of bone turnover.

      Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol.
    

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Werner's syndrome with osteoporosis and low serum insulin-like
        growth factor 1 level Patient treated on protocol 04-9215300 "Metabolic and Skeletal
        Effects of Exogenous Recombinant Human Insulin-Like Growth Factor"
      
